Loading insider details...
Beta
Latest Form 4 (Jun 17, 2026): Grant/Award of 3,135 APRE shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 17, 2026 | Aprea Therapeutics, Inc. (APRE) | Grant/Award | 3,135 | n/a |
| Dec 11, 2025 | Aprea Therapeutics, Inc. (APRE) | Purchase | 21,459 | $25.0K |
| Jun 9, 2025 | Aprea Therapeutics, Inc. (APRE) | Grant/Award | 1,045 | n/a |
| Oct 25, 2024 | Aprea Therapeutics, Inc. (APRE) | Sale | 6,462 | $29.6K |
| Oct 17, 2024 | Aprea Therapeutics, Inc. (APRE) | Purchase | 30,000 | $131.7K |
| Oct 16, 2024 | Aprea Therapeutics, Inc. (APRE) | Purchase | 190 | $490.20 |
| Jun 21, 2024 | Aprea Therapeutics, Inc. (APRE) | Grant/Award | 1,045 | n/a |
| Aug 25, 2023 | Aprea Therapeutics, Inc. (APRE) | Conversion | 4,009,690 | n/a |
| Aug 1, 2022 | Aprea Therapeutics, Inc. (APRE) | Grant/Award | 5,995 | n/a |